FOXO4 10 mg: Research Peptide Profile

FOXO4 10mg: FOXO4-DRI (Forkhead box protein O4 – D-retro-inverso) is a synthetic senolytic peptide designed to selectively target and eliminate senescent cells—often called “zombie cells”—that accumulate with age and contribute to age-related dysfunction. This profile provides essential information for researchers working with this compound.

What is FOXO4-DRI?

FOXO4-DRI is a modified peptide that specifically disrupts the interaction between the FOXO4 and p53 proteins within the nucleus of senescent cells . This disruption triggers apoptosis (programmed cell death) in senescent cells while leaving healthy, non-senescent cells largely unaffected .

Key Identifiers:

• Type: D-retro-inverso peptide

• Mechanism: Senolytic (selective elimination of senescent cells)

• Purity: Typically ≥98% for research-grade material

• Status: Research compound only; not FDA-approved for human use

Mechanism of Action

FOXO4-DRI functions through a targeted mechanism involving the p53 tumor suppressor pathway:

The FOXO4-p53 Interaction:

• In senescent cells, the FOXO4 protein binds to phosphorylated p53 (p53-pS15) within the nucleus, preventing p53’s nuclear exclusion and thereby inhibiting apoptosis—this allows senescent cells to survive despite their damaged state 

• FOXO4-DRI competitively binds to the transactivation domain 2 (TAD2) of p53 with higher affinity than FOXO4 itself, disrupting the FOXO4-p53 interaction 

Apoptosis Triggering:

• Disruption allows phosphorylated p53 to translocate from the nucleus to the cytoplasm 

• Cytoplasmic p53 activates BAX and cleaved caspase-3, initiating the apoptosis execution phase 

• This pathway is transcription-independent, allowing rapid cell death 

Research Applications

Vascular Aging

Recent 2026 research published in Frontiers in Bioengineering and Biotechnology demonstrated that FOXO4-DRI effectively suppresses aortic aging and improves aortic function in both naturally aged and induced aging mouse models . The peptide specifically targets senescent endothelial cells via the p53/BCL-2/Caspase-3 signaling pathway .

Keloid Fibroblasts

A 2025 study in Communications Biology identified FOXO4-DRI as a promising therapeutic approach for keloids—pathological scars characterized by fibroblast senescence and apoptosis resistance . The peptide promotes nuclear exclusion of p53-pS15, selectively inducing apoptosis in keloid senescent fibroblasts .

Chemotherapy-Induced Senescence

FOXO4-DRI has demonstrated efficacy in reducing senescent cell burden and neutralizing toxic side effects induced by chemotherapy drugs like doxorubicin in mouse models .(FOXO4 10mg).

Safety & Regulatory Status

Critical Limitations

Human Data Lacking: As of late 2025, there are no published, peer-reviewed human clinical trials for FOXO4-DRI . All efficacy and safety data are derived from preclinical studies (rodent models and cell culture) .

Regulatory Status:

• FDA Approval: Not approved for any indication 

• Human Use: No legal pathway for human therapeutic use

• Research Status: Available exclusively from authorized research suppliers 

Theoretical Risks

p53 Tumor Suppressor Pathway Interference: Because FOXO4-DRI intervenes in the p53 pathway—a critical tumor suppressor—there is a theoretical concern about potential oncogenic risk, though the peptide’s mechanism aims to free p53 to kill senescent cells rather than inhibit it .

Potential Off-Target Effects: While evidence suggests selectivity for senescent cells, the heterogeneity of senescent cell populations means some healthy or quiescent cells may share features, presenting a risk of unintended apoptosis .

Beneficial Senescent Cell Clearance: Senescent cells play beneficial roles in wound healing and development; their blanket elimination may have unintended consequences .

Reconstitution & Handling

• Product Form: Lyophilized powder

• Recommended Storage: Store at -20°C; protect from light

• Reconstitution: Sterile water or bacteriostatic water for research use

• Handling: For in vitro research use only; appropriate laboratory safety protocols required

Frequently Asked Questions

What is the primary mechanism of FOXO4-DRI?

FOXO4-DRI is a senolytic peptide that selectively induces apoptosis in senescent cells by disrupting the FOXO4-p53 interaction, allowing p53 to translocate to the cytoplasm and trigger cell death .

Is FOXO4-DRI FDA-approved?

No. FOXO4-DRI is not FDA-approved for any indication and is available exclusively for research purposes .

What does research show about FOXO4-DRI?

Preclinical research demonstrates efficacy in reducing senescent cell burden in aged mice, improving vascular function, and showing potential in fibrosis models such as keloids . However, no human clinical trial data has been published .

What are the risks associated with FOXO4-DRI?

Theoretical risks include interference with the p53 tumor suppressor pathway, potential off-target effects on healthy cells, and unintended consequences of clearing cells that may have beneficial roles in development and wound healing .

Are there human studies on FOXO4-DRI?

As of early 2026, there are no published, peer-reviewed human clinical trials for FOXO4-DRI. The translation from mouse models to humans remains unproven .